Generic name: Pralatrexate
Mechanism of action
Folypra is a folate analog that selectively enters cells expressing reduced folate carrier (RFC), an oncofetoprotein found in tumor cells. Upon entry into the malignant cell, it competitively inhibits dihydrofolate reductase (DHFR) and thymidylate synthase. This inhibition results in the depletion of thymidine monophosphate (TMP) so that the cancer cell is unable to synthesize DNA and RNA and is forced to undergo apoptosis.
Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
Dosage form and strength
Clear yellow aqueous injectable solution in single-dose vial containing pralatrexate at a concentration of 20 mg/mL
Undiluted doses of Folypra should be administered intravenously over 3-5 minutes via the side port of a free-flowing 0.9% sodium chloride injection.